AstraZeneca's Enhertu Meets Primary Endpoint in First-Line Lung Cancer Trial
Phase III data shows antibody drug conjugate delays disease progression in HER2-mutant non-small cell lung cancer versus standard chemotherapy-immunotherapy combination.
Trial Results
AstraZeneca announced positive high-level results from the DESTINY-Lung04 Phase III trial, showing that Enhertu (trastuzumab deruxtecan) demonstrated "a statistically significant and clinically meaningful improvement in progression-free survival" versus global standard of care as first-line treatment for patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-small cell lung cancer (6-K filing, 2026-08-17).
The comparator arm consisted of platinum-pemetrexed doublet chemotherapy plus pembrolizumab, which represents the current global standard of care for this patient population. The trial will continue to evaluate secondary endpoints including overall survival (6-K filing, 2026-08-17).
Target Population and Unmet Need
HER2 mutations are identified in approximately 2-4% of patients with NSCLC, predominantly affecting younger women and people with no smoking history (6-K filing, 2026-08-17). These mutations "have been independently associated with cancer cell growth and poor prognosis, with an increased incidence of brain metastases," according to the filing.
While the current standard immunotherapy and platinum-based chemotherapy combination has shown survival benefits in NSCLC, "many patients do not respond to 1st-line treatment and experience disease progression, underscoring the need for additional treatment options" (6-K filing, 2026-08-17).
Study Design
DESTINY-Lung04 is a global, randomized, open-label trial that enrolled 454 patients across sites in Asia, Europe and North America (6-K filing, 2026-08-17). Patients received either Enhertu at 5.4mg/kg or standard of care chemotherapy-immunotherapy combination in a 1:1 randomization stratified by smoking history and presence or history of brain metastasis.
The safety profile observed in the trial "was generally consistent with its known profile, with no new safety concerns identified," according to the company (6-K filing, 2026-08-17).
Regulatory and Commercial Context
Enhertu, a HER2-directed antibody drug conjugate jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, is already approved in more than 80 countries for previously treated metastatic NSCLC with HER2 mutations based on results from the DESTINY-Lung02 and DESTINY-Lung05 trials (6-K filing, 2026-08-17).
Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca, said the trial "becoming the first Phase III trial to demonstrate a progression-free survival benefit versus the global standard of care in this first-line setting" supports "the potential for Enhertu to move earlier in the treatment of HER2-mutant non-small cell lung cancer" (6-K filing, 2026-08-17).
The company plans to present the DESTINY-Lung04 data at an upcoming medical meeting and share results with global regulatory authorities (6-K filing, 2026-08-17).
Market Background
Lung cancer remains the leading cause of cancer-related death globally, with approximately 2.6 million new cases and 1.8 million deaths reported worldwide in 2024 (6-K filing, 2026-08-17). NSCLC accounts for approximately 85% of all lung cancer cases, and prognosis is particularly poor for metastatic disease, with only about 10% of patients surviving beyond five years after diagnosis (6-K filing, 2026-08-17).
According to MarginX data, AstraZeneca is scheduled to present at the SEB Nordic Large Cap Seminar on August 18, 2026, and the Handelsbanken Life Science Innovation Day on August 25, 2026.
This article was generated by MarginX from the 6-K filing on 2026-08-17. It is not investment advice.